" class="no-js "lang="en-US"> Neurimmune - Medtech Alert
Monday, April 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Neurimmune | Pharmtech Focus

Neurimmune

About Neurimmune

Neurimmune

Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune discovered aducanumab for Alzheimer’s disease together with a team of researchers at the University of Zurich and licensed it to Biogen.

Neurimmune’s Reverse Translational Medicine technology platform translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates. Besides aducanumab, Neurimmune discovered cinpanemab for Parkinson’s disease, the anti-tau antibody BIIB076 for Alzheimer’s disease, the anti-miSOD1 antibody AP-101 for amyotrophic lateral sclerosis, and the anti-ATTR antibody NI006 for cardiomyopathy. These programs are currently evaluated in clinical trials.

Related Story

Industry News

 Neurimmune Expands Drug Discovery Collaboration with Ono Pharmaceutical in the Field of Neurodegenerative Diseases | Pharmtech Focus

Neurimmune Expands Drug Discovery Collaboration with Ono Pharmaceutical in the Field of Neurodegenerative Diseases

January 17 2022

Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with […]

Industry News

 Neurimmune Enters into a Collaboration and License Agreement with AstraZeneca to Develop and Commercialize NI006 | Pharmtech Focus

Neurimmune Enters into a Collaboration and License Agreement with AstraZeneca to Develop and Commercialize NI006

January 7 2022

Neurimmune AG today announced that it has entered into an exclusive global collaboration and license […]

Diseases

 FDA Approval of Aducanumab | Pharmtech Focus

FDA Approval of Aducanumab

June 10 2021

Neurimmune welcomes the news that the U.S. Food and Drug Administration (FDA) has approved Biogen‘s […]